Safety of 6′‐Sialyllactose (6′‐SL) sodium salt as a novel food pursuant to Regulation (EU) 2015/2283

Safety of 6′‐Sialyllactose (6′‐SL) sodium salt as a novel food pursuant to Regulation (EU) 2015/2283

Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 6′‐Sialyllactose (6′‐SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human‐iden...

Full description

Bibliographic Details
Main Authors:	EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch‐Ernst, John Kearney, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Karl Heinz Engel, Thomas Frenzel, Marina Heinonen, Rosangela Marchelli, Monika Neuhäuser‐Berthold, Morten Poulsen, Josef Rudolf Schlatter, Henk van Loveren, Paolo Colombo, Helle Katrine Knutsen
Format:	Article
Language:	English
Published:	Wiley 2020-05-01
Series:	EFSA Journal
Subjects:	6′‐Sialyllactose 6′‐SL human milk oligosaccharide HMO HiMO novel food
Online Access:	https://doi.org/10.2903/j.efsa.2020.6097

Similar Items

Safety of 6′‐sialyllactose (6′‐SL) sodium salt produced by a derivative strain (Escherichia coli NEO6) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2023-06-01)

Safety of 6′‐sialyllactose (6’‐SL) sodium salt produced by derivative strains of Escherichia coli BL21 (DE3) as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-12-01)

Safety of 3′‐sialyllactose (3′‐SL) sodium salt produced by a derivative strain (Escherichia coli NEO3) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2023-09-01)

Safety of 3’‐sialyllactose (3’‐SL) sodium salt produced by derivative strains of Escherichia coli BL21 (DE3) as a Novel Food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-05-01)

Safety of lacto‐N‐tetraose (LNT) produced by derivative strains of Escherichia coli BL21 (DE3) as a Novel Food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-05-01)

Safety of 3‐fucosyllactose (3‐FL) produced by a derivative strain of Escherichia coli BL21 (DE3) as a Novel Food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-05-01)

Safety of 2′‐fucosyllactose (2’‐FL) produced by a derivative strain (APC199) of Corynebacterium glutamicum ATCC 13032 as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-12-01)

Safety of 3‐fucosyllactose (3‐FL) produced by a derivative strain of Escherichia coli K‐12 DH1 as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2023-06-01)

Safety of 2′‐fucosyllactose (2’‐FL) produced by a derivative strain (Escherichia coli SGR5) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2023-11-01)

Dietary supplementation of 3′-sialyllactose or 6′-sialyllactose elicits minimal influence on cognitive and brain development in growing pigs
by: Rebecca K. Golden, et al.
Published: (2024-01-01)

Human milk oligosaccharides 3′-sialyllactose and 6′-sialyllactose protect intestine against necrotizing enterocolitis damage induced by hypoxia
by: Ziyu Huang, et al.
Published: (2021-11-01)

Determining the safety and efficacy of dietary supplementation with 3ˊ-sialyllactose or 6ˊ-sialyllactose on growth, tolerance, and brain sialic acid concentrations
by: Rebecca K. Golden, et al.
Published: (2023-10-01)

6’-sialyllactose ameliorates the ototoxic effects of the aminoglycoside antibiotic neomycin in susceptible mice
by: Tawfik Abou Assale, et al.
Published: (2023-12-01)

Safety of the extension of use of 2’‐fucosyllactose (2’‐FL) and lacto‐N‐neotetraose (LNnT) as novel foods in food supplements for infants pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-05-01)

Safety of the extension of use of 2′‐fucosyllactose (2′‐FL) as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2023-11-01)

Safety of lacto‐N‐neotetraose (LNnT) produced by derivative strains of E. coli BL21 as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2020-11-01)

Evaluation of 6′-Sialyllactose Sodium Salt Supplementation to Formula on Growth and Clinical Parameters in Neonatal Piglets
by: Marcia H. Monaco, et al.
Published: (2020-04-01)

Safety of lacto‐N‐tetraose (LNT) as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2019-12-01)

Sialyllactose Enhances the Short-Chain Fatty Acid Production and Barrier Function of Gut Epithelial Cells via Nonbifidogenic Modification of the Fecal Microbiome in Human Adults
by: Yohei Sato, et al.
Published: (2024-01-01)

Safety of the extension of use of 2’‐fucosyllactose/difucosyllactose (2’‐FL/DFL) mixture and lacto‐N‐tetraose (LNT) as novel foods in food supplements for infants pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-03-01)

Pharmacokinetics and clinical efficacy of 6′-sialyllactose in patients with GNE myopathy: Randomized pilot trial
by: Young-Eun Park, et al.
Published: (2023-12-01)

Safety of lacto‐N‐fucopentaose I/2’‐fucosyllactose (LNFP‐I/2’‐FL) mixture as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2023-12-01)

3′sialyllactose and 6′sialyllactose enhance performance in endurance‐type exercise through metabolic adaptation
by: Jesus Arellano Spadaro, et al.
Published: (2023-10-01)

Multivalent Sialyllactose-Levan-Conjugated Gold Nanoparticles for Efficient Interaction with and Colorimetric Detection of Influenza A Virus
by: Sun-Jung Kim, et al.
Published: (2021-07-01)

Effect of sialyllactose on growth performance and intestinal epithelium functions in weaned pigs challenged by enterotoxigenic Escherichia Coli
by: Qiming Duan, et al.
Published: (2022-03-01)

Simultaneous Quantification of 3′- and 6′-Sialyllactose in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study
by: Seok-In Jang, et al.
Published: (2021-02-01)

Development and Validation of a Bioanalytical Method for 3′- and 6′-Sialyllactose in Minipig Liver and Kidney Using Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Analysis of Tissue Distribution
by: Han Young Eom, et al.
Published: (2020-12-01)

Determination of 3′-Sialyllactose in Edible Bird’s Nests and the Effect of Stewing Conditions on the 3′-Sialyllactose Content of Edible Bird’s Nest Products
by: Xiaojiang Zhang, et al.
Published: (2023-02-01)

Scientific opinion on the tolerable upper intake level for vitamin B6
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2023-05-01)

Exposure to 3′Sialyllactose-Poor Milk during Lactation Impairs Cognitive Capabilities in Adulthood
by: Edoardo Pisa, et al.
Published: (2021-11-01)

Sialyllactose and Galactooligosaccharides Promote Epithelial Barrier Functioning and Distinctly Modulate Microbiota Composition and Short Chain Fatty Acid Production In Vitro
by: Olaf Perdijk, et al.
Published: (2019-02-01)

Corrigendum: Sialyllactose and Galactooligosaccharides Promote Epithelial Barrier Functioning and Distinctly Modulate Microbiota Composition and Short Chain Fatty Acid Production In Vitro
by: Olaf Perdijk, et al.
Published: (2019-04-01)

Safety of cellobiose as a novel food pursuant to regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-11-01)

3′-Sialyllactose Protects SW1353 Chondrocytic Cells From Interleukin-1β-Induced Oxidative Stress and Inflammation
by: Ahreum Baek, et al.
Published: (2021-04-01)

Safety of apple fruit cell culture biomass as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2023-07-01)

Safety of the extension of use of plant sterol esters as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2020-06-01)

Safety of bovine milk osteopontin as a Novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-05-01)

Safety of mung bean protein as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2021-10-01)

Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2021-09-01)

Safety of Wolffia globosa powder as a Novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods, Food Allergens (NDA), et al.
Published: (2021-12-01)